[{"id":"450196e9-e0ad-47bf-a736-4b3fdabb7b6e","acronym":"NCI-2019-03057","url":"https://clinicaltrials.gov/study/NCT03953898","created_at":"2021-01-18T19:27:50.729Z","updated_at":"2024-07-02T16:34:37.850Z","phase":"Phase 2","brief_title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","source_id_and_acronym":"NCT03953898 - NCI-2019-03057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"8420d34e-5720-4abb-8b0f-9d930a4e3baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03212274","created_at":"2021-01-18T15:50:38.215Z","updated_at":"2024-07-02T16:35:02.706Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT03212274","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-17"},{"id":"8458f7b4-ba3b-4835-b691-1de379b3d9f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05921760","created_at":"2023-06-27T14:08:24.970Z","updated_at":"2024-07-02T16:35:10.760Z","phase":"Phase 1/2","brief_title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","source_id_and_acronym":"NCT05921760","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-09"},{"id":"f25cf478-f7d0-48ec-a823-1e8a5b6955d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764474","created_at":"2022-03-09T14:53:09.433Z","updated_at":"2024-07-02T16:35:19.376Z","phase":"Phase 1","brief_title":"A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH","source_id_and_acronym":"NCT04764474","lead_sponsor":"Hutchmed","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ranosidenib (HMPL-306)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 02/28/2021","start_date":" 02/28/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-14"},{"id":"4332101d-7ce0-4281-baf4-5b9d31806fda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303519","created_at":"2022-03-31T17:52:38.349Z","updated_at":"2024-07-02T16:35:29.269Z","phase":"Phase 2","brief_title":"Safusidenib Phase 2 Study in IDH1 Mutant Glioma","source_id_and_acronym":"NCT05303519","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • safusidenib (DS-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-11-14"},{"id":"b6751a5d-2b30-4afb-9a75-5fbf38411c4e","acronym":"ClarIDHy","url":"https://clinicaltrials.gov/study/NCT02989857","created_at":"2021-01-17T17:13:55.238Z","updated_at":"2024-07-02T16:35:57.587Z","phase":"Phase 3","brief_title":"Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)","source_id_and_acronym":"NCT02989857 - ClarIDHy","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 187","initiation":"Initiation: 02/20/2017","start_date":" 02/20/2017","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 05/17/2021","study_completion_date":" 05/17/2021","last_update_posted":"2023-01-16"}]